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Abstract
Background
Atrial fibrillation is a large and growing burden across all types of healthcare. Both incidence
and prevalence are expected to double in the next 20 years, with huge impact on hospital
admissions, costs and patient quality of life. Patient wellbeing determines the management
strategy for atrial fibrillation, including the use of rhythm control therapy and the clinical suc-
cess of heart rate control. Hence, evaluation of quality of life is an emerging and important
part of the assessment of patients with atrial fibrillation. Although a number of question-
naires to assess quality of life in atrial fibrillation are available, a comprehensive overview
of their measurement properties is lacking.
Methods and Results
We performed a systematic review of the measurement properties of atrial fibrillation-spe-
cific health-related quality of life questionnaires. Methodological quality was assessed
using the Consensus based Standards for selection of health Measurement Instruments
(COSMIN) checklist, with measurement properties rated for quality against optimal criteria
and levels of evidence. We screened 2,216 articles, of which eight articles describing five
questionnaires were eligible for inclusion: Atrial Fibrillation 6 (AF6), Atrial Fibrillation Effect
on QualiTy-of-Life (AFEQT), Atrial Fibrillation Quality of Life Questionnaire (AFQLQ), Atrial
Fibrillation Quality of Life (AFQoL), and Quality of Life in Atrial Fibrillation (QLAF). Good
reliability (internal consistency and test-retest reliability) was demonstrated for AF6,
AFEQT, AFQLQ and AFQoL. Content, construct and criterion validity were positively rated
only in AFEQT. Responsiveness was positively rated only in AFEQT, but with limited
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evidence. Overall, AFEQT showed strong positive evidence for 2 of 9 measurement proper-
ties, compared to one for AFQoL and none for the remaining questionnaires.
Interpretation
Given the low ratings for many measurement properties, no single questionnaire can be
recommended, although AFEQT performed strongest. Further studies to robustly assess
reliability, validity and responsiveness of AF-specific quality of life questionnaires are
required. This review consolidates the current evidence for quality of life assessment in
patients with atrial fibrillation and identifies priority areas for future research.
Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is predicted to double in
prevalence over the next 20 years. It is not only associated with adverse prognosis, but accounts
for considerable healthcare expenditure. [1] Numerous studies have identified a substantial
reduction in health-related quality of life (QoL) in AF populations. [2] Patients with AF experi-
ence symptoms such as palpitations, exercise intolerance, dizziness and dyspnea, which fre-
quently limit capacity to undertake daily activities. [3, 4]
Apart from anticoagulation to prevent strokes, current management of AF is focused on
reducing symptoms and improving QoL. [5] Even well-established therapies in AF have proven
to have little impact on death and other adverse outcomes, including rate and rhythm control
therapy. [6–9] Although the fundamental reason for pursing such therapies is to improve QoL,
there is limited appreciation of how to measure QoL in clinical practice.
A variety of both generic and AF-specific questionnaires are available to assess patient-
reportedQoL. [10] Generic patient reported outcome measures (PROMs), such as the SF-36
and EQ-5D questionnaires, have the advantage of allowing comparison of QoL in patients with
different diseases, but are less sensitive to the effects of a single disease on QoL. [11] With the
growing burden of AF, the relatively high cost of treatment, and the appreciation of QoL as a
treatment objective, there has been substantial interest in the development of AF-specific
PROMs for use in both clinical research and routine practice. However, these have yet to enter
routine clinical practice, in part due to concerns about their validity and responsiveness. [12]
Our objective was to perform a systematic review of the measurement properties of disease-
specific PROMs measuringQoL in AF, assessing studies which designed and validated the
questionnaires. We aim to provide clinicians with an understanding of whether these instru-
ments would likely be of value in research and clinical practice.We utilized a comprehensive
methodology from the Consensus based Standards for selection of health Measurement Instru-
ments (COSMIN) group [13], which includes rigorous assessment of validity, reliability, and
responsiveness of QoL questionnaires.
Methods
Eligibility criteria and search strategy
We included all studies that examined at least one or more measurement properties of a dis-
ease-specificPROMmeasuringQoL in patients with AF (aged 18 years and older).We permit-
ted inclusion of studies with interviewer-basedadministration, as long as questionnaires were
self-reported by patients. Studies were required to be published as a full-text article. Articles
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were excluded if the article failed to specify the type of tool utilized. There was no restriction on
language, date of publication or type of AF.
A systematic search was performed in Medline, EMBASE, PsycINFO and CINAHL from
inception until the 15th February 2015 and in the Cochrane library from 1993 to 9th March
2015. The search strategy (see S1 Appendix) consisted of 3 filters composed of search terms for
the following: (1) AF; (2) PROMs; and (3) measurement properties. The latter two filters were
developed at the University of Oxford and VUUniversity Medical Center [14] respectively
(available at www.cosmin.nl). All filters were adapted for each database. Reference lists of the
included studies were also manually searched in addition to articles that cited them.
This reviewwas prospectively registered with the PROSPERO database of systematic
reviews (http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015016600).
In this paper, we report on our primary outcome which addresses the quality of AF-specific
PROMs using the COSMINmethodology.
Data collection and synthesis
For each study, two investigators independently extracted and tabulated data on a standardized
data extraction form. Discrepancies and missing data were resolved by group discussion,
reference to the original publication and additional adjudication. Two studies published in Jap-
anese [15, 16] were first translated by a Cardiologist fluent in both the Japanese and English
languages.
The COSMIN checklist was used by two independent reviewers to assess the methodological
quality of the included studies. [13] This tool distinguishes three main domains (reliability,
validity and responsiveness), subdivided into nine measurement properties. For each measure-
ment property, numerous standards are included in the form of questions to determine the
quality of the study. Each item per measurement property is scored as excellent, fair, good or
poor, with the lowest rating determining the overall quality score for that study (“worst score
counts” method).
Measurement properties were rated for quality against criteria for optimal measurement
properties. Each result was rated as either positive (+), negative (-) or indeterminate (?), pro-
viding that methodological quality was not poor. [17] Table 1 summarizes the definitions of
the nine measurement properties assessed and the preferred methods for their assessment,
based on the COSMIN taxonomy, with detailed criteria presented in S1 Table. [18, 19] Best
evidence synthesis was performed by applying levels of evidence developed by Terwee et al.
(www.cosmin.nl), combining the ratings of study quality with the strength of findings to deter-
mine an overall judgement for each questionnaire, as demonstrated in S2 Table.
Results
Study characteristics
The results of the search strategy are outlined in Fig 1. After removal of duplicates, the litera-
ture search yielded 2,216 articles of which eight were included in the final analysis. [15, 16, 20–
25] A summary of studies excluded at the full-text stage is presented in S3 Table.
We identified five questionnaires developed and validated for the assessment of quality of
life in AF: Atrial Fibrillation 6 (AF6) [24, 25], Atrial Fibrillation Effect on QualiTy-of-Life
(AFEQT) [20], Atrial Fibrillation Quality of Life Questionnaire (AFQLQ) [15, 16], Atrial
Fibrillation Quality of Life (AFQoL) [21, 22], and Quality of Life in Atrial Fibrillation (QLAF).
[23]
The characteristics of the questionnaires included in this review and the study populations
in which their measurement properties were evaluated are summarized in Table 2. The QoL
Quality of Life Assessment in Atrial Fibrillation
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questionnaires were assessed in a variety of geographical locations, however patients were of a
similar mean age (62–67 years). Women were under-represented in all of the cohorts (20–
43%). The type of AF varied in the individual studies, although on average there was an even
split between paroxysmal and more persistent forms.
QoL instruments
Results of the assessment of validity for each instrument are detailed in S4 Table and for reli-
ability and responsiveness in S5 Table. It was not possible to rate any of the instruments in rela-
tion to measurement error, as statistical evaluations were not reported. Similarly, there were no
data on cross cultural validity, and hence study quality and instrument ratings were not per-
formed for these domains. A summary of findings is presented in Fig 2. Best evidence synthesis
to provide an overall appraisal of each questionnaire is detailed in Table 3, limited by the avail-
ability of only one or two published articles for each questionnaire. Below, we concisely review
the main results for the individual QoL instruments alphabetically.
1. AF6. AF6 was evaluated in 2 articles, both utilizing the same cohort of 111 patients
recruited in Sweden. [24, 25]
Reliability: The quality of the study was fair for internal consistency and reliability, with both
of these measurement properties rated positively. Internal consistency was only evaluated in
Table 1. Definitions of measurement properties.
Measurement
Property
Definition Quality criteria for positive rating *
1. Reliability
Internal Consistency The extent to which items of a questionnaire are
interrelated in their underlying construct
Cronbach’s alpha (+ if0.70)
Test-retest reliability The proportion of the total variance in the
measurements which is due to true differences between
patients.
Intra-class correlation coefficient or weighted Kappa (+ if0.7 or
Pearson’s r0.8)
Measurement Error The extent of change not attributable to the true
alteration in the patient’s quality of life
Minimal important change (MIC) (+ if MIC > smallest detectable change
or MIC outside the limits of agreement)
2. Validity
Content Validity Assesses whether the questionnaire adequately reflects
the construct of interest
Relevance to target population (+ if relevant to the construct measured
and comprehensive)
Construct Validity
• Structural Validity Consistency between factor structure and the
underlying construct
Factor analysis (+ if factors explain at least 50% of variance)
• Hypothesis testing • Convergent: Determines whether expected similar
domains between measurement tools are in fact
similar
• Discriminant: Determines whether expected dissimilar
domains between measurement tools are in fact
unrelated
Correlation coefficient (+ if0.5 with an instrument measuring the same
construct, or75% in accordance with hypotheses and concordance
with stated constructs)
• Cross-cultural
validity
Assesses whether a translated questionnaire
adequately reflects the original questionnaire
Comparison of different language versions (+ if original factor structure
confirmed or no important differences)
Criterion Validity Similarity between scores derived through the
questionnaire against those from a gold standard
Correlation coefficient with an accepted gold standard measure (+ if
0.7)
3. Responsiveness
Response to clinical
change
The ability to detect change in quality of life over time Correlation and hypothesis concordance (+ if correlation0.50 with
instrument measuring same construct or75% in accordance with
hypotheses or area under the curve0.70)
* For a full description of the criteria for measurement properties, see S1 Table.
doi:10.1371/journal.pone.0165790.t001
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patients who underwent direct current cardioversion (whichmay not be representative of general
AF patients and can variably affect QoL depending on success). Test-retest reliability was only
assessed in 9 patients who had failed cardioversion, with 3 of the 6 items (limitations in daily life
due to AF, discomfort due to AF and fatigue due to AF) associated with poor coefficient values.
Validity: Content validity and hypothesis testing of this instrument were rated as indetermi-
nate due to poor ratings for reportedmethodology. For criterion validity, appropriate statistics
were not reported. Structural validity assessment was deemed of fair quality overall, although
statistical methods and handling of missing data were excellent and the instrument was posi-
tively rated for this measurement property.
Responsiveness: Only assessed in a single study of poormethodological quality, which did
not describe the construct of the comparator (SF-36) or detail the handling of missing data or
the underlying hypotheses. [25]
Synthesis: Two measurement properties was positively rated based on limited evidence.
2. AFEQT. AFEQT was evaluated in a single article composed of 213 patients recruited
from hospitals across North America. [20] The population was predominantly of European
descent and English-speaking.
Fig 1. Selection of studies flowchart. Study inclusion flowchart. See S1 Appendix for search strategy.
doi:10.1371/journal.pone.0165790.g001
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Reliability: The quality of the study was excellent for internal consistency and fair for test-
retest reliability, due to inadequate information regarding the environment of questionnaire
administration. Bothmeasurement properties were rated as positive.
Validity: The quality of the study on content validity was deemedmethodologically excel-
lent, whereas the quality of the study regarding structural validity, hypothesis testing and
criterion validity were rated fair as the handling of missing data was not detailed. All of these
validity aspects were rated positive.
Responsiveness: Although there was excellent description of hypotheses, comparators and
methods, the overall quality of the study was rated fair, as responsiveness was only assessed in
cohorts of patients who received an intervention (66 patients with medication adjustment and
76 with ablation). It was unclear how missing data were handled, and the expected or achieved
correlations were not reported. The responsiveness of the instrument was however, rated as
positive (data presented in S5 Table). Comparison with generic QoLmeasures (SF-36 and EQ-
5D) resulted in smaller effect sizes, although the responsiveness of the AFEQT was comparable
to the Toronto AF Symptoms Check List and Atrial Fibrillation Severity Scale.
Synthesis: Two measurement properties showed strong positive evidence, and four were
positive based on limited evidence.
3. AFQLQ. AFQLQwas studied in two articles, both recruiting patients from Japan. [15, 16]
Reliability: Assessed in a single article, [16] quality was categorized as methodically fair for
both internal consistency and test-retest reliability. Although the sample size was>100, both
measurement properties were marked down due to inadequate information on missing data
and potential differences in test conditions during resampling. Both measurement properties
were rated positive.
Validity: Structural validity was investigated in a single article. [15] The study was methodo-
logically fair as assessment was only performed in a small number of patients and the handling
Table 2. Characteristics of included studies.
Instrument Population characteristics Questionnaire characteristics
Geographical
location
Sample
size of
studies
Mean age
(years ± SD)
Women
(%)
Type of AF (%) Number
of items
Domains Response
options
AF6[24, 25] Sweden 111 67 ± 12 20% Not reported 6 Dyspnea at rest, dyspnea on
exertion, limitation in daily life
due to AF, discomfort due to
AF, fatigue due to AF, anxiety
due to AF
10 point Likert
scale
AFEQT[20] Canada & US 213 62 ± 12 42% Paroxysmal
66%, persistent
29%, permanent
5%
20 Symptoms, daily activities,
treatment concerns, treatment
satisfaction
7 point Likert
scale
AFQLQ[15,
16]
Japan 40 & 172 64 ± 10 24% Paroxysmal
57%, persistent
43%
26 Type and frequency of
symptoms, severity of
symptoms, psychological
aspects, limitation in daily life
4–6 options of
ranging severity
dependent on
domain
AFQoL[21,
22]
Spain 112 & 417 62 ± 12 35% Paroxysmal
53%, permanent
47%
18 Psychological, physical, sexual
activity
5 point Likert
scale
QLAF[23] Brazil 63 63 ± 12 43% Paroxysmal
38%, persistent
32%, permanent
30%
22 Palpitations, chest pain,
breathlessness, dizziness,
drugs, direct current
cardioversion, ablation
Letters assigned
to text options
and yes/no tick
boxes
doi:10.1371/journal.pone.0165790.t002
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Fig 2. Summary of assessment. For each measurement property, the PROM is assessed for methodological quality of the study (excellent,
good, fair or poor) and given an overall rating (positive [+], negative [-] or indeterminate/unknown [?]) for the results. A level of evidence was
applied, combining the number and quality of the studies with the strength of findings. Studies that have poor quality are given an ‘indeterminate
/unknown’ rating due to the limited level of evidence. For AFQoL, reliability was assessed differently in the two related studies. * Insufficient data
were available to rate this criterion. See Table 1 for assessment criteria.
doi:10.1371/journal.pone.0165790.g002
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of missing data was not clearly reported. The instrument was positively rated for structural
validity. No information was available on other validity aspects.
Responsiveness: Assessed in a single article [16], this study was rated as methodically poor.
It was unclear if changes occurred in the patients during the interim period, either in treatment
or symptoms, and the study failed to detail expected hypotheses.
Synthesis: Three positive measurement properties with limited evidence, however there was
insufficient data to rate 5 out of 9 measurement properties.
4. AFQoL. AFQoLwas assessed in two articles recruiting Spanish patients from hospitals
across Madrid and Bilbao. [21, 22]
Reliability: An evaluation of internal consistency was rated as methodologically fair in both
articles, whereas test-retest was rated fair in one [21] and poor in the other [22], due to the rela-
tively small sample size, uncertainty if the test conditions were the same, and lack of details
regarding the handling of missing data. The instrument was rated positive for internal consis-
tency in both articles [21, 22], but indeterminate for test-retest reliability.
Validity: Content validity and structural validity were assessed in a single article. [22] The
quality of content validity assessment was methodologically excellent, while structural validity
was deemed fair due to omission of details on the handling of missing data. The instrument
was rated positively for both of these measurement properties. The study on hypothesis testing
was methodologicallypoor due to a lack of detail on the self-perceived health status scale
employed, hence the instrument was rated indeterminate. Criterion validity was assessed in a
single article [21], with fair study quality but an indeterminate rating as QoL was compared
with patients post-myocardial infarction.
Responsiveness: Assessed in a single article of poormethodologically quality [21], as only
correlations between baseline SF-36 and AFQoLwere reported.
Synthesis: One measurement property showed strong positive evidence, and two were posi-
tive based on limited evidence.
5. QLAF. QLAF was assessed in a single article consisting of 63 patients recruited from
centers across Brazil. [23]
Reliability: The assessment of internal consistency was rated as methodically poor as factor
analysis was not performed. Study quality for test-retest reliability was fair, due to the small
sample size and insufficient detail on the handling of missing items. The instrument was rated
as positive for this measurement property.
Validity: Content validity was rated as methodologicallypoor, as the questionnaire was admin-
istered to a small target population and there was no patient involvement in the questionnaire
Table 3. Synthesis of results.
Measurement property AF6 AFEQT AFQLQ AFQoL QLAF
Internal Consistency + +++ + + ?
Test-retest reliability ? +/- + +/- +
Measurement error n/r n/r n/r n/r n/r
Content Validity ? +++ n/r +++ ?
Structural Validity + + + + n/r
Hypothesis Testing ? + n/r ? ?
Cross Cultural n/r n/r n/r n/r n/r
Criterion Validity ? + n/r +/- ?
Responsiveness ? + ? ? ?
“+++” or “- - -” = strong positive or negative evidence; “++” or “- -” = moderate positive or negative evidence; “+” or “-” = limited positive or negative evidence;
“+/-” = conflicting findings; “?” = unknown, due to poor methodological quality; n/r = not rated due to insufficient data. See S2 Table for assessment criteria.
doi:10.1371/journal.pone.0165790.t003
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design. Prior hypotheses regarding expected correlations between the SF-36 and QLAFwere not
stated when undertakinghypothesis testing and appropriate statistics were not used during crite-
rion validity assessment; thus both construct and criterion validity were rated as methodologically
poor.
Responsiveness: Poor study quality due to a lack of appropriate statistical analysis.
Synthesis: One measurement property showed positive evidence based on limited evidence.
Discussion
This comprehensive systematic review identified five health-related QoL questionnaires used
to assess AF populations, and evaluated their measurement properties using the COSMIN
approach. To our knowledge, this is the first study to systematically evaluate the methodologi-
cal quality of studies and the measurement properties of QoL questionnaires in AF patients.
Our key finding was the lack of robust psychometric testing of any of the currently available
AF-specific QoL instrument, particularly for measurement error. We found deficiencies in
most instruments in relation to reliability, construct and criterion validity, but particularly in
the responsiveness of questionnaires. The results raise important questions about the use of
these instruments in research and daily clinical practice, and suggest the need for further evalu-
ation before implementation.
Quality of life encompasses a person's perceptions of their physical and psychological state,
social relationships and environment. [26] Many generic and disease-specificquestionnaires
exist to assess QoL in AF patients. The Short Form 36 (SF-36) is perhaps the most common
generic QoLmeasure [4], and often used as a gold-standard comparator in the validation of
other questionnaires (although as there is no ‘true’ gold-standard measure, criterion validity
remains problematic to adequately appraise). Genericmeasures are useful to determine overall
QoL in the population, particularly to quantify health utility or for comparing between diseases
and populations. However, they may not be as sensitive to the effect of a single disease on QoL
[11], whereas disease-specificquestionnaires assess domains more relevant to the particular
condition and may provide more targeted information to inform shared-decisionmaking. [10]
There is increasing interest in evaluating the effect of management strategies on QoL among
AF patients, but for clinical confidence, the tool used should demonstrate good responsiveness,
in addition to being a reliable and valid measure. Indeed, a recently developedQoL question-
naire for patients undergoing catheter ablation for cardiac arrhythmias has demonstrated
responsiveness to clinical change. [27]
This review utilized the COSMIN approach for performing the systematic review. The COS-
MIN taxonomy was developed after an international Delphi study [13], using a consensus of
terminology across validation studies and allowing standardized objective assessment of mea-
surement properties. Further, the group have developed standards (the COSMIN checklist) for
how measurement properties should be evaluated [28] and provide a structured protocol for
undertaking such reviews to a high quality (http://www.cosmin.nl/). The COSMINmethodol-
ogy has been incorporated into several other reviews to evaluate PROM assessment across a
variety of diseases, including chronic obstructive pulmonary disease [29], osteoarthritis [30],
cancer [31], multiple sclerosis [32] and Parkinson’s Disease. [32] Whilst the standards within
COSMIN are high, the thresholds for reliability are in line with the International Society for
Quality of Life Research (ISOQOL) requirements. [33] It could be argued that high standards
are needed to drive improvements in the methodologyof development and validation of
PROMs, and allow clinicians to have greater confidence in their use. As with any system based
on scientific judgment, our results based on the COSMIN approach are only one component of
evaluating quality of life questionnaires.
Quality of Life Assessment in Atrial Fibrillation
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A specific limitation of our reviewwas the inclusion of questionnaires developed and vali-
dated before the COSMIN checklist becamewidely available, which may have impacted on the
scores assigned for methodological quality. This may be less of an issue in future reviews,
where validation studies would ideally have incorporated the COSMIN checklist. There are
other methodologies available for evaluating PROMs, for example the Federal Drug Adminis-
tration scheme, which utilizes broadly similar assessment categories. [34] However, the COS-
MIN approach offers a more quantifiable appraisal of measurement properties. Secondly, the
inclusion of two Japanese papers requiring translation meant these articles were assessed by a
sole reviewer, which may impact on internal validity. We are also limited to the ‘general’ AF
populations studied, whereas patients with specific comorbidities may respond differently to
PROMs. For example, heart failure is a common comorbidity in AF [35] that is underrepre-
sented in the studies evaluated.
The content of these questionnaires demonstrates some similarities among them, with 4 out
of 5 examining the type and/or frequency of symptoms (the only exception being AFQoL), and
all except QLAF assessing the impact of AF on daily activities, physical and psychological func-
tioning, albeit to differing extent. Synthesis of results in our review showed that AFEQT dem-
onstrated strong positive evidence for internal consistency and content validity and AFQoL
showed strong positive evidence for content validity. All other questionnaires failed to provide
sufficient evidence to make a strong positive rating. Neither measurement error nor cross-cul-
tural validity were appropriately assessed in any study and there were limited data for respon-
siveness, which we were only able to rate for AFEQT. Where study quality was poor, or ratings
indeterminate, this does not mean that a particular questionnaire performed badly, only that
the evidencewas limited. For example, AFQoL, in addition to AFEQT, demonstrated strong
positive evidence for content validity, an important measurement property that is the founda-
tion of a goodQoL questionnaire.
Refinements to AF PROMs are ongoing, and AFQLQ was recently updated to a second ver-
sion, demonstrating good intra- and inter-observer reproducibility and internal consistency in
40 AF patients. [36] However, even with full information on psychometric properties, clinical
validity requires further appraisal in large-scale AF populations, a review of which is beyond
the scope of this methodological assessment. Apart from AFEQT [37], there is limited informa-
tion about the minimally important change seen with these questionnaires.
With the growing burden of AF and the equivocal benefit of rate or rhythm-control strategies
in improving mortality [6–9], there is increasing importance of QoL assessment. Over 34 differ-
ent QoL questionnaires have been utilized in published AF studies [10] emphasizing the current
lack of consensus on the best instrument to assess QoL. Our assessment of methodological qual-
ity suggests that reported results for the available instruments should be treated with caution
and that further, more robust validation is required to determine if these measures are appropri-
ate to assess QoL in clinical populations. However, adequate measurement properties are just
one aspect of whether a QoL tool is useful in research and clinical practice. Cost, ease of admin-
istration, time taken and patient acceptability are also important considerations. [29] Future
studies are clearly required that address the detectable change in scores, as well as the respon-
siveness of the questionnaire to changes in patient symptoms and management strategies in the
clinical setting. One such study that is due to commence shorty is the RAte Control Therapy
Evaluation in Atrial Fibrillation (RATE-AF) randomized trial. [38]
Conclusion
Using the systematic COSMIN approach, we have identified clear deficiencies in the five avail-
able instruments for assessing disease-specificquality of life in patients with atrial fibrillation.
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The strongest performing tool was AFEQT, but further evidence for test-retest reliability,
measurement error and responsiveness are required before recommending routine clinical
implementation.
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